Topic:

Venture Capital

Latest Headlines

Latest Headlines

Novartis teams with Qualcomm on $100M digital health fund

The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.

10X Genomics exits stealth mode with $80M, plan to improve Illumina tech

10X Genomics has exited stealth mode with $80 million in VC funding and a plan to solve a significant sequencing problem without going head to head with Illumina. The Pleasanton, CA-based startup is set to unveil an add-on for Illumina sequencers that improves their ability to map long reads of DNA.

Personalis raises $33M to scale up pharma-facing genomics operation

Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.

Big rounds push 2014 biotech venture funding to near-record $6B

With a big assist from Moderna's recent monster round, the biotech industry came within a rounding error of breaking the record for new venture investing in 2014, racking up $5.96 billion in total investments in a frenzied year of deals, data and buyouts, according to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.

Canadian VC CTI unveils a $112M new biotech fund

CTI Life Sciences, a Montreal-headquartered biotech backer, has put together a $112 million new purse, scouting for promising startups in Canada and abroad.

NeuroPhage wraps a $27M round to advance its Alzheimer's drug

Cambridge, MA's NeuroPhage banked an additional $10 million in Series D cash, bringing its latest round to $27 million and filling out the biotech's war chest as it marches toward the clinic with a treatment for neurodegenerative disease.

Top biotech investor NEA outlines plans for another $2.5B-plus venture fund

In a sign of the times, leading life sciences venture maven David Mott and his colleagues at New Enterprise Associates have begun raising a whopping $2.5 billion venture fund--less than three years after rolling out its latest fund with $2.6 billion.

Euro VC Fountain unveils a $101M biotech fund

Fountain Healthcare Partners put together an €85 million ($101 million) new purse, money the Irish investor plans to pour into biotech startups.

Orphazyme hauls in $24M to advance its rare disease contender

Danish biotech Orphazyme raised a €20 million ($24 million) B round to fund its work on rare lysosomal storage disorders, tapping an investor syndicate that includes Novo Nordisk's venture arm as it rolls toward Phase II trials.

China's Hua Medicine bags $25M for diabetes R&D

Shanghai's Hua Medicine hauled in a $25 million B round to advance its work on a new treatment for diabetes, bringing in investors from the U.S. and China as it moves toward late-stage development.